Randomized trial · people
Orforglipron: heart events no worse than insulin in ACHIEVE-4
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In adults with type 2 diabetes and high heart risk, orforglipron did not raise major heart events compared with insulin glargine over about 2 years, with more gut side effects but fewer low blood sugar episodes.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 2749
- Published
- 2026
- Journal
- Lancet
What they tested
The team tested whether daily oral orforglipron is no worse than insulin glargine for major heart and blood vessel events in adults with type 2 diabetes at higher heart risk.
How the study was done
A phase 3, randomized, open-label trial at 317 sites in 16 countries and territories. It enrolled 2749 adults with type 2 diabetes, a BMI of 25 kg/m2 or more, and established heart or chronic kidney disease, who got either once-daily oral orforglipron at the highest dose they tolerated (up to 36 mg capsule) or once-daily injected insulin glargine, with a median follow-up of 2 years.

What they found
The main outcome was MACE-4, a combined count of heart-related death, non-fatal heart attack, non-fatal stroke, or a hospital stay for unstable angina (chest pain from poor blood flow to the heart). It occurred in 57 (4.2%) of 1358 people on orforglipron and 67 (5.0%) of 1343 on insulin glargine, a hazard ratio (relative risk over time) of 0.84 (95% CI 0.59-1.20), which met the trial's test for being no worse than insulin. Gut side effects were reported in 62.1% on orforglipron vs 14.2% on insulin glargine, and were the most common reason people stopped orforglipron, while clinically significant or severe low blood sugar occurred in 6.8% vs 19.2%. There were 19 deaths (1.4%) on orforglipron and 43 (3.2%) on insulin glargine, and all but one, in the insulin group, were judged unrelated to treatment.
What it doesn’t show
The trial was built to show orforglipron was no worse than insulin glargine, not to show it lowers heart events, and it was open-label, so people knew which treatment they got. It only included people with type 2 diabetes and existing heart or kidney disease, and it was funded by Eli Lilly and Company.
The paper
Klein et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026.
The compound
More studies on Orforglipron
- Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1Randomized trial · people · 2025
- Orforglipron: food lowered drug exposure by 17.6% to 23.7%Clinical trial · people · 2024
- Every study on Orforglipron
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.